The Crystal Structure of the Hsp90-LA1011 Complex and the Mechanism by Which LA1011 May Improve the Prognosis of Alzheimer’s Disease
Functional changes in chaperone systems play a major role in the decline of cognition and contribute to neurological pathologies, such as Alzheimer’s disease (AD). While such a decline may occur naturally with age or with stress or trauma, the mechanisms involved have remained elusive. The current m...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/7/1051 |
| _version_ | 1827733651912130560 |
|---|---|
| author | S. Mark Roe Zsolt Török Andrew McGown Ibolya Horváth John Spencer Tamás Pázmány László Vigh Chrisostomos Prodromou |
| author_facet | S. Mark Roe Zsolt Török Andrew McGown Ibolya Horváth John Spencer Tamás Pázmány László Vigh Chrisostomos Prodromou |
| author_sort | S. Mark Roe |
| collection | DOAJ |
| description | Functional changes in chaperone systems play a major role in the decline of cognition and contribute to neurological pathologies, such as Alzheimer’s disease (AD). While such a decline may occur naturally with age or with stress or trauma, the mechanisms involved have remained elusive. The current models suggest that amyloid-β (Aβ) plaque formation leads to the hyperphosphorylation of tau by a Hsp90-dependent process that triggers tau neurofibrillary tangle formation and neurotoxicity. Several co-chaperones of Hsp90 can influence the phosphorylation of tau, including FKBP51, FKBP52 and PP5. In particular, elevated levels of FKBP51 occur with age and stress and are further elevated in AD. Recently, the dihydropyridine LA1011 was shown to reduce tau pathology and amyloid plaque formation in transgenic AD mice, probably through its interaction with Hsp90, although the precise mode of action is currently unknown. Here, we present a co-crystal structure of LA1011 in complex with a fragment of Hsp90. We show that LA1011 can disrupt the binding of FKBP51, which might help to rebalance the Hsp90-FKBP51 chaperone machinery and provide a favourable prognosis towards AD. However, without direct evidence, we cannot completely rule out effects on other Hsp90-co-chaprone complexes and the mechanisms they are involved in, including effects on Hsp90 client proteins. Nonetheless, it is highly significant that LA1011 showed promise in our previous AD mouse models, as AD is generally a disease affecting older patients, where slowing of disease progression could result in AD no longer being life limiting. The clinical value of LA1011 and its possible derivatives thereof remains to be seen. |
| first_indexed | 2024-03-11T01:15:12Z |
| format | Article |
| id | doaj.art-08be2b23ecf04e69a5cf2cce0b6b8737 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-11T01:15:12Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-08be2b23ecf04e69a5cf2cce0b6b87372023-11-18T18:30:42ZengMDPI AGBiomolecules2218-273X2023-06-01137105110.3390/biom13071051The Crystal Structure of the Hsp90-LA1011 Complex and the Mechanism by Which LA1011 May Improve the Prognosis of Alzheimer’s DiseaseS. Mark Roe0Zsolt Török1Andrew McGown2Ibolya Horváth3John Spencer4Tamás Pázmány5László Vigh6Chrisostomos Prodromou7Department of Biochemistry and Biomedicine, University of Sussex, Brighton BN1 9QG, UKInstitute of Biochemistry, Biological Research Centre, 6726 Szeged, HungarySussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Brighton BN1 9QG, UKInstitute of Biochemistry, Biological Research Centre, 6726 Szeged, HungarySussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Brighton BN1 9QG, UKGedeon Richter Plc, 1475 Budapest, HungaryInstitute of Biochemistry, Biological Research Centre, 6726 Szeged, HungaryDepartment of Biochemistry and Biomedicine, University of Sussex, Brighton BN1 9QG, UKFunctional changes in chaperone systems play a major role in the decline of cognition and contribute to neurological pathologies, such as Alzheimer’s disease (AD). While such a decline may occur naturally with age or with stress or trauma, the mechanisms involved have remained elusive. The current models suggest that amyloid-β (Aβ) plaque formation leads to the hyperphosphorylation of tau by a Hsp90-dependent process that triggers tau neurofibrillary tangle formation and neurotoxicity. Several co-chaperones of Hsp90 can influence the phosphorylation of tau, including FKBP51, FKBP52 and PP5. In particular, elevated levels of FKBP51 occur with age and stress and are further elevated in AD. Recently, the dihydropyridine LA1011 was shown to reduce tau pathology and amyloid plaque formation in transgenic AD mice, probably through its interaction with Hsp90, although the precise mode of action is currently unknown. Here, we present a co-crystal structure of LA1011 in complex with a fragment of Hsp90. We show that LA1011 can disrupt the binding of FKBP51, which might help to rebalance the Hsp90-FKBP51 chaperone machinery and provide a favourable prognosis towards AD. However, without direct evidence, we cannot completely rule out effects on other Hsp90-co-chaprone complexes and the mechanisms they are involved in, including effects on Hsp90 client proteins. Nonetheless, it is highly significant that LA1011 showed promise in our previous AD mouse models, as AD is generally a disease affecting older patients, where slowing of disease progression could result in AD no longer being life limiting. The clinical value of LA1011 and its possible derivatives thereof remains to be seen.https://www.mdpi.com/2218-273X/13/7/1051Alzheimer’s diseaseHsp90FKBP51immunopilinLA1011co-chaperone |
| spellingShingle | S. Mark Roe Zsolt Török Andrew McGown Ibolya Horváth John Spencer Tamás Pázmány László Vigh Chrisostomos Prodromou The Crystal Structure of the Hsp90-LA1011 Complex and the Mechanism by Which LA1011 May Improve the Prognosis of Alzheimer’s Disease Biomolecules Alzheimer’s disease Hsp90 FKBP51 immunopilin LA1011 co-chaperone |
| title | The Crystal Structure of the Hsp90-LA1011 Complex and the Mechanism by Which LA1011 May Improve the Prognosis of Alzheimer’s Disease |
| title_full | The Crystal Structure of the Hsp90-LA1011 Complex and the Mechanism by Which LA1011 May Improve the Prognosis of Alzheimer’s Disease |
| title_fullStr | The Crystal Structure of the Hsp90-LA1011 Complex and the Mechanism by Which LA1011 May Improve the Prognosis of Alzheimer’s Disease |
| title_full_unstemmed | The Crystal Structure of the Hsp90-LA1011 Complex and the Mechanism by Which LA1011 May Improve the Prognosis of Alzheimer’s Disease |
| title_short | The Crystal Structure of the Hsp90-LA1011 Complex and the Mechanism by Which LA1011 May Improve the Prognosis of Alzheimer’s Disease |
| title_sort | crystal structure of the hsp90 la1011 complex and the mechanism by which la1011 may improve the prognosis of alzheimer s disease |
| topic | Alzheimer’s disease Hsp90 FKBP51 immunopilin LA1011 co-chaperone |
| url | https://www.mdpi.com/2218-273X/13/7/1051 |
| work_keys_str_mv | AT smarkroe thecrystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT zsolttorok thecrystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT andrewmcgown thecrystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT ibolyahorvath thecrystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT johnspencer thecrystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT tamaspazmany thecrystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT laszlovigh thecrystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT chrisostomosprodromou thecrystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT smarkroe crystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT zsolttorok crystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT andrewmcgown crystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT ibolyahorvath crystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT johnspencer crystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT tamaspazmany crystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT laszlovigh crystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease AT chrisostomosprodromou crystalstructureofthehsp90la1011complexandthemechanismbywhichla1011mayimprovetheprognosisofalzheimersdisease |